Publication
Date | SPC No. | SPC
Category | Details
Rows may repeat to show multiple inventors or applicants depending on "Sort By" |
|---|
24 November 2021
(Journal 6914)
| SPC/GB09/004 | Entered Into Force | Applicant: DOW AGROSCIENCES LLC
9330 Zionsville Road, Indianapolis, Indiana, 45268-1054, United States of America
Product: Pyroxsulam
Product Type: Plant Protection
Authorised: UK MAPP 14089 6 August 2008
Authorised Extension:
Patent No: EP1242425
Title: N-(5,7-dimethoxyl[1,2,4]triazolo[1,5-a]pyrimidin-2-yl) arylsulfonamide compounds and their use as herbicides
SPC No: SPC/GB09/004
Date entered into force: 2 November 2021
Effective Period Expires On: 5 August 2023 |
24 November 2021
(Journal 6914)
| SPC/GB14/033 | Granted | Applicant: H.Lundbeck A/S
Ottiliavej 9, 2500, Valby, Copenhagen, Denmark
Product: Vortioxetine or a pharmaceutically acceptable acid addition salt thereof
Product Type: Medicinal
Authorised: UK EU/1/13/891/001-040 20 December 2013
Authorised Extension:
Patent No: EP1436271
Title: Phenyl-piperazine derivatives as serotonin reuptake inhibitors
SPC No: SPC/GB14/033
Date Granted: 2 November 2021
Maximum Period Expires On: 1 October 2027 |
24 November 2021
(Journal 6914)
| SPC/GB16/047 | Granted | Applicant: Bayer Healthcare LLC
100 Bayer Boulevard,, PO Box 915, Whippany, NJ 07981, United States of America
Product: Octocog Alfa
Product Type: Medicinal
Authorised: UK EU/1/15/1076 22 February 2016
Authorised Extension:
Patent No: EP1641825
Title: Use of molecular chaperones for the enhanced production of secreted, recombinant proteins in mammalian cells.
SPC No: SPC/GB16/047
Date Granted: 2 November 2021
Maximum Period Expires On: 15 March 2029 |
24 November 2021
(Journal 6914)
| SPC/GB17/013 | Granted | Applicant: Merck Sharp & Dohme Corp.
126 East Lincoln Avenue, Rahway, NJ 07065-0907, USA
Product: Elbasvir or a pharmaceutically acceptable salt thereof.
Product Type: Medicinal
Authorised: UK EU/1/16/1119 26 July 2016
UK PLGB 53095/0082 26 July 2016
Authorised Extension:
Patent No: EP2410844
Title: Inhibitors of hepatitis C virus replication.
SPC No: SPC/GB17/013
Date Granted: 2 November 2021
Maximum Period Expires On: 25 July 2031 |
24 November 2021
(Journal 6914)
| SPC/GB17/014 | Granted | Applicants: Merck Sharp & Dohme Corp. and MSD Italia S.r.l.
126 East Lincoln Avenue, Rahway, NJ 07065-0907, USA
Product: Grazoprevir or a pharmaceutically acceptable salt thereof.
Product Type: Medicinal
Authorised: UK EU/1/16/1119 26 July 2016
UK PLGB 53092/0082 26 July 2016
Authorised Extension:
Patent No: EP2310095
Title: Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors.
SPC No: SPC/GB17/014
Date Granted: 2 November 2021
Maximum Period Expires On: 25 July 2031 |
24 November 2021
(Journal 6914)
| SPC/GB17/020 | Granted | Applicant: Janssen Pharmaceutica NV
Turnhoutseweg, 2340 Beerse, Belgium
Product: Eluxadoline or a pharmaceutically acceptable salt thereof
Product Type: Medicinal
Authorised: UK EU/1/16/1126/001-006 21 September 2016
Authorised Extension:
Patent No: EP1725537
Title: Novel compounds as opioid receptor modulators
SPC No: SPC/GB17/020
Date Granted: 1 November 2021
Maximum Period Expires On: 13 March 2030 |
24 November 2021
(Journal 6914)
| SPC/GB17/051 | Granted | Applicant: DOW AGROSCIENCES LLC
9330 Zionsville Road, Indianapolis, Indiana 46268-1054, United States of America
Product: A combination of halauxifen-methyl and florasulam
Product Type: Plant Protection
Authorised: DK 64-88 29 February 2016
UK MAPP17938 0763of2017 10 March 2017
Authorised Extension:
Patent No: EP2180790
Title: Synergistic herbicidal composition containing certain pyridine carboxylic acids and certain cereal and rice herbicides
SPC No: SPC/GB17/051
Date Granted: 1 November 2021
Maximum Period Expires On: 28 February 2031 |
24 November 2021
(Journal 6914)
| SPC/GB17/059 | Granted | Applicant: Richter Gedeon Nyrt.
Gyömrői út 19-21, 1103 Budapest, Hungary
Product: Cariprazine, optionally in the form of a salt, including Cariprazine hydrochloride
Product Type: Medicinal
Authorised: UK EU/1/17/1209/001-040 17 July 2017
UK PLGB 04854/0173 17 July 2017
UK PLGB 04854/0174 17 July 2017
UK PLGB 04854/0175 17 July 2017
UK PLGB 04854/0176 17 July 2017
Authorised Extension:
Patent No: EP1663996
Title: (Thio)Carbamoyl-cyclohexane derivatives as D3/D2 receptor antagonists
SPC No: SPC/GB17/059
Date Granted: 2 November 2021
Maximum Period Expires On: 20 May 2029 |
24 November 2021
(Journal 6914)
| SPC/GB17/074 | Granted | Applicants: Novartis AG and Astex Therapeutics Ltd.
Lichtstrasse 35, 4056 Basel, Swtizerland
Product: Ribociclib or a pharmaceutically acceptable salt thereof
Product Type: Medicinal
Authorised: UK EU/1/17/1221/001-012 24 August 2017
UK PLGB 00101/1100 24 August 2017
Authorised Extension:
Patent No: EP2331547
Title: Pyrrolopyrimidine compounds as CDK inhibitors
SPC No: SPC/GB17/074
Date Granted: 1 November 2021
Maximum Period Expires On: 23 August 2032 |
24 November 2021
(Journal 6914)
| SPC/GB17/078 | Granted | Applicant: Orexigen Therapeutics, Inc.
3344 North Torrey Pines Court, Suite 200, La Jolla, CA 92037, United States of America
Product: Naltrexone or a pharmaceutically acceptable salt thereof, in particular naltrexone hydrochloride, and bupropion or a pharmaceutically acceptable salt thereof, in particular bupropion hydrochloride.
Product Type: Medicinal
Authorised: UK EU/1/14/988 30 March 2015
UK PLGB 50742/0001 30 March 2015
Authorised Extension:
Patent No: EP2316456
Title: Compositions for affecting weight loss comprising an opioid antagonist and bupropion
SPC No: SPC/GB17/078
Date Granted: 1 November 2021
Maximum Period Expires On: 20 April 2029 |
